Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ) with Topical Therapy Using Active Oxygen Gel

• Published in: Clinical, cosmetic and investigational dentistry Vol. 16; pp. 249 - 254
• Main Authors: Deliberador, Tatiana Miranda, Stutz, Carlos, Sartori, Elisa, Kluppel, Leandro, de Freitas, Rubens Moreno
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2024; Dove Medical Press
• Subjects: Active oxygen; biphosphonate; Bones; Care and treatment; Health aspects; jaw; Metronidazole; Necrosis; osteonecrosis; oxygen; Patient education; Radiotherapy; reactive oxygen species; wound healing; Wounds and injuries; bisphosphonate; jaw; wound healing; osteonecrosis; oxygen; reactive oxygen species
• ISSN: 1179-1357; 1179-1357
• DOI: 10.2147/CCIDE.S462051

Medication-related osteonecrosis of the jaw (MRONJ) can be a debilitating complication that can arise in patients who took or are taking antiresorptive (including bisphosphonates) or antiangiogenic agents, leading to visible bone or a fistula that continues for more than eight weeks, without any history of radiotherapy. This clinical case aimed to describe the treatment of MRONJ with topical active oxygen therapy using blue m oral gel. A 63-year-old female patient that had been taking weekly sodium alendronate (70 mg) for four years by oral via, presented discomfort and implant movement in the #46 region, by that underwent surgical extraction of the implant. After three months the patient returned and was diagnosed with MRONJ. Initially, conventional therapies were performed, including surgical debridement and antibiotic therapy, but without success. The patient still had clinical signs of osteonecrosis six months after the implant extraction. The entire socket was then filled with blue m oral gel by topical application. The patient was instructed to continue applying the gel to the region every 8 hours for 15 days. After this period, the patient returned, and it was observed that the wound was in the healing process, with the presence of epithelialized tissue and without bone exposure. The 2-year clinical follow-up showed the lesion had healed entirely, and a new implant was installed. After the osseointegration period, the final prosthesis was placed. The patient remains under clinical follow-up. Therefore, it can be concluded that the application of blue m oral gel in this clinical case assisted in the recovery of the osteonecrosis lesion.